CD38 and Miyoshi myopathy: It has been selected as a target for numerous monoclonal therapeutic antibodies targeting MM cells, such as Elotuzumab and Daratumumab, as targeting CD38 has been shown to facilitate the lysis of MM plasma cells through various antibody-mediated mechanisms such as antibody-dependent cell cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP), significantly improving the outcomes of patients with relapsed or refractory MM [20,21,22,23,24].